Showing posts with label glucose. Show all posts
Showing posts with label glucose. Show all posts

Monday, August 22, 2011

Treating obesity via brain glucose sensing

ScienceDaily (July 26, 2011) — The past two decades have witnessed an epidemic spread of obesity-related diseases in Western countries. Elucidating the biological mechanism that links overnutrition to obesity could prove crucial in reducing obesity levels. In the July 26 issue of PLoS Biology, Dr. Dongsheng Cai and his research team at Albert Einstein College of Medicine describe a pathway that directs the brain to sense the body's glucose dynamics, and they find that a defect of this glucose sensing process contributes to the development of obesity and related disease. Importantly, the team also found that correction of this defect can normalize the whole-body energy balance and treat obesity.See Also:Health & MedicineObesityDiet and Weight LossFitnessMind & BrainDieting and Weight ControlNutrition ResearchNeuroscienceReferenceAppetiteBlood sugarSkeletal muscleDiabetes mellitus type 2

The hypothalamus in the brain plays a key role in controlling energy and body weight balance. To maintain balance between energy intake and energy expenditure, the hypothalamus constantly gauges the whole-body's energy levels by sampling circulating hormones (e.g. insulin and leptin) as well as nutrients (e.g., glucose). Although we know quite a bit about the hormonal pathways in the hypothalamic regulation of feeding, the mechanisms for hypothalamic nutrient sensing are much less clear. Moreover, a causal link between a nutrient sensing defect and obesity remains to be established. The team led by Dr. Cai discovered a novel role of a protein complex, hypoxia-inducible factor (HIF), in hypothalamic glucose sensing and whole-body energy balance in mice.

HIF is a nuclear transcription factor which induces hypoxia response. When tissue oxygen level is low, HIF is activated to promote cellular metabolic adaption and survival. Recent research has appreciated the involvement of HIF in the metabolism of tumor cells. "However, an intriguing but unexplored question is whether HIF can be important for the regulation of whole-organism metabolism, and if so, which tissue and cells are responsible." says Cai, who is an expert in neuroendocrinology and metabolism.

Cai and his group examined HIF in the hypothalamus and, surprisingly, found that it can be activated by glucose and that this regulation was associated with appetite control in mice. In identifying the cellular and molecular basis, the team found that in response to glucose, HIF acts in a unique group of hypothalamic nutrient-sensing neurons to induce expression of POMC gene -- a gene which has been known to play a key part in hypothalamic control of feeding and body weight. Most excitingly, the team demonstrated the therapeutic potential of targeting hypothalamic HIF to control obesity. By enhancing the hypothalamic HIF activity via gene delivery, mice become resistant to obesity despite the condition of nutritional excess.

"It was an exciting discovery," explains Cai, "Our study is the first to show that beyond its classical oxygen-sensing function in many cells, HIF in the hypothalamic neurons can sense glucose to control the whole-body balance of energy intake and expenditure which is critical for body weight homeostasis." Overall, this study reveals a crucial role for neuronal HIF in bridging the brain's glucose sensing with the brain's regulation of body weight and metabolic physiology. These findings also highlight a potential implication for developing neuronal HIF activators in treating and preventing obesity and related diseases.

Email or share this story:

Tuesday, August 16, 2011

Test measuring blood glucose control may help predict risk of CVD events in patients with diabetes

ScienceDaily (July 25, 2011) — Measuring hemoglobin A 1c (HbA 1c ) levels in patients with diabetes is associated with improvement in models for predicting risk for cardiovascular disease (CVD), according to a report published Online First on July 25 by Archives of Internal Medicine, one of the JAMA/Archives journals.See Also:Health & MedicineDiabetesCholesterolWounds and HealingAsthmaMultiple Sclerosis ResearchDiseases and ConditionsReferenceDiabetic dietBlood sugarDiabetes mellitus type 2Hyperglycemia

According to background information in the article, diabetes has been recognized as a risk factor for CVD. But recent research indicates that the level of risk may vary among patients with diabetes. "Simulated cost-benefit analyses have suggested that this variability in CVD risk could provide an opportunity for tailored preventive therapy in diabetic patients," write the authors. They sought to investigate the predictive value of HbA 1c levels; this test reflects the average blood glucose level over the previous two to three months, and generally indicates how well the diabetes is being managed.

Nina P. Paynter, Ph.D., from Brigham and Women's Hospital, Boston, and colleagues, used data from participants of the Women's Health Study and the Physician's Health Study II. To generate the model, they included data from 24,674 women, of whom 685 had diabetes at baseline, and 11,280 men, of whom 563 had diabetes at baseline. Questionnaires provided participants' health history, and baseline blood samples were evaluated for cholesterol, C-reactive protein and HbA 1c levels. The researchers followed up participants for incident (new cases) CVD; women were followed up for a median (midpoint) of 10.2 years and men for a median of 11.8 years.

During follow-up, 125 cardiovascular events occurred in the 685 women with diabetes and 170 events occurred in the 563 men with diabetes (compared with 666 and 1,382 events, respectively, in participants without diabetes). In both sexes, including HbA 1c into risk modeling for CVD improved prediction of CVD compared to classification of all diabetic participants as high risk (10-year risk at least 20 percent). This association was especially pronounced in women. The risk modeling demonstrated that 71.9 percent of female diabetic participants had less than a 20 percent risk of CVD over 10 years, whereas only 24.5 percent of male diabetic participants had a predicted 10-year CVD risk of less than 20 percent. In models that included a term for HbA 1c , there was substantial improvement in CVD risk prediction for women, and more modest improvement in risk prediction for men. Using a yes/no term for diabetes instead of HbA 1c also improved prediction over classification as high risk in both men and women. In women, however, HbA 1c further improved prediction over the yes/no term.

"We found that in these large population-based cohorts of both men and women, presence of diabetes alone did not confer a 10-year risk of CVD higher than 20 percent, and measurement of HbA 1c level in diabetic subjects improved risk prediction compared with classification as cardiovascular risk equivalent," note the researchers. They propose that the difference in risk between the sexes may be partly attributed to the increase in CVD risk with age and the delayed risk in women. The authors call for further research to replicate their results, but conclude, "Our findings suggest that the improvement in CVD risk prediction, and possibly calibration, obtained with adding HbA 1c levels is highest in lower-risk populations."

This work was carried out with support from F. Hoffmann-La Roche Ltd; and grants from the National Heart Lung and Blood Institute, the National Cancer Institute and the Donald W. Reynolds Foundation, Las Vegas.


Commentary: Cardiovascular Risk Stratification, Hemoglobin A 1c , and the Tempo of Translation

An accompanying commentary by Mark J. Pletcher, M.D., M.P.H., from the University of California, San Francisco, notes that the Adult Treatment Panel III (ATP III) guidelines and other cardiovascular disease (CVD) prevention guidelines will be updated soon.

"One specific guideline refinement up for consideration this year is the approach to CVD risk stratification in patients with diabetes," writes Pletcher. He states that under current ATP III guidelines, diabetes is considered a "CHD

Monday, July 25, 2011

Pocket chemistry: DNA helps glucose meters measure more than sugar

ScienceDaily (July 24, 2011) — Glucose meters aren't just for diabetics anymore. Thanks to University of Illinois chemists, they can be used as simple, portable, inexpensive meters for a number of target molecules in blood, serum, water or food.See Also:Health & MedicineGenesDiet and Weight LossHuman BiologyMatter & EnergyOrganic ChemistryMicroarraysChemistryReferenceBiosensorBlood sugarBlood testDrug discovery
Chemistry professor Yi Lu and postdoctoral researcher Yu Xiang published their findings in the journal Nature Chemistry.
"The advantages of our method are high portability, low cost, wide availability and quantitative detection of a broad range of targets in medical diagnostics and environmental monitoring," Lu said. "Anyone could use it for a wide range of detections at home and in the field for targets they may care about, such as vital metabolites for a healthy living, contaminants in their drinking water or food, or potential disease markers."
A glucose meter is one of the few widely available devices that can quantitatively detect target molecules in a solution, a necessity for diagnosis and detection, but only responds to one chemical: glucose. To use them to detect another target, the researchers coupled them with a class of molecular sensors called functional DNA sensors.
Functional DNA sensors use short segments of DNA that bind to specific targets. A number of functional DNAs and RNAs are available to recognize a wide variety of targets.
They have been used in the laboratory in conjunction with complex and more expensive equipment, but Lu and Xiang saw the potential for partnering them with pocket glucose meters.
The DNA segments, immobilized on magnetic particles, are bound to the enzyme invertase, which can catalyze conversion of sucrose (table sugar) to glucose. The user adds a sample of blood, serum or water to the functional DNA sensor to test for drugs, disease markers, contaminants or other molecules. When the target molecule binds to the DNA, invertase is released into the solution. After removing the magnetic particle by a magnet, the glucose level of the sample rises in proportion to the amount of invertase released, so the user then can employ a glucose meter to quantify the target molecule in the original sample.
"Our method significantly expands the range of targets the glucose monitor can detect," said Lu, who also is affiliated with the Beckman Institute for Advanced Science and Technology and with the Frederick Seitz Materials Research Lab at U. of I. "It is simple enough for someone to use at home, without the high costs and long waiting period of going to the clinics or sending samples to professional labs."
The researchers demonstrated using functional DNA with glucose meters to detect cocaine, the disease marker interferon, adenosine and uranium. The two-step method could be used to detect any kind of molecule that a functional DNA or RNA can bind.
Next, the researchers plan to further simplify their method, which now requires users to first apply the sample to the functional DNA sensor and then to the glucose meter.
"We are working on integrating the procedures into one step to make it even simpler," Lu said. "Our technology is new and, given time, it will be developed into an even more user-friendly format."
The U.S. Department of Energy, the National Institutes of Health and the National Science Foundation supported this work.
Email or share this story: